Abstract. We analyzed the spatial diversity of tumor habitats, regions with distinctly different intensity characteristics of a tumor, using various measurements of habitat diversity within tumor regions. These features were then used for investigating the association with a 12-month survival status in glioblastoma (GBM) patients and for the identification of epidermal growth factor receptor (EGFR)-driven tumors. T1 postcontrast and T2 fluid attenuated inversion recovery images from 65 GBM patients were analyzed in this study. A total of 36 spatial diversity features were obtained based on pixel abundances within regions of interest. Performance in both the classification tasks was assessed using receiver operating characteristic (ROC) analysis. For association with 12-month overall survival, area under the ROC curve was 0.74 with confidence intervals [0.630 to 0.858]. The sensitivity and specificity at the optimal operating point (threshold ¼ 0.5) on the ROC were 0.59 and 0.75, respectively. For the identification of EGFR-driven tumors, the area under the ROC curve (AUC) was 0.85 with confidence intervals [0.750 to 0.945]. The sensitivity and specificity at the optimal operating point (threshold ¼ 0.166) on the ROC were 0.76 and 0.83, respectively. Our findings suggest that these spatial habitat diversity features are associated with these clinical characteristics and could be a useful prognostic tool for magnetic resonance imaging studies of patients with GBM.
Introduction
Glioblastoma (GBM) is the most common primary brain tumor known for its aggressive malignant behavior. Generally, the treatment of GBM involves surgical resection followed by a combination of radiation therapy and temozolomide. Despite multimodality treatment, the median survival time of GBM patients remains poor between 12 and 15 months. 1, 2 Medical image analysis plays an essential role for phenotyping disease and has tremendous applications in clinical decision support. Several computer-based medical image analyses have been studied in GBM. [3] [4] [5] [6] Specifically, identifying the imagederived phenotype of the tumor is essential to understand and quantify treatment response and prognosis. For example, gray-level intensity heterogeneity within a tumor is indicative of multiple, potentially distinct subregions within the tumor and analysis of such heterogeneity has the potential to aid treatment of GBM. [7] [8] [9] Tumor texture has been investigated as one surrogate for tumor heterogeneity. It has been shown to be associated with the malignancy of the tumor 10 and can provide essential prognostic information. [11] [12] [13] Several texture analyses have been investigated in multiple tumor contexts based on imaging methods, such as computed tomography, positron emission tomography, and magnetic resonance imaging (MRI). [14] [15] [16] [17] [18] In an orthogonal approach, researchers have investigated the spatial heterogeneity of tumors using the concept of radiologically defined "tumor habitats," where the tumor regions have distinctly different MRI-derived intensity characteristics. 8 Cancer is considered a disease that involves the clonal evolution of genes associated with cancer risk 19 and the spatial cellular heterogeneity of tumors is clearly evident in the imaging characteristics of tumors.
Many tumors show spatially heterogeneous patterns in contrast to enhancement in their medical images and such spatial patterns of the tumor represent various biological tissue properties based on water content, cellular density, fibrosis, and necrosis. In ecology, methods such as spatial species diversity or biodiversity analysis 20 have been proven to be useful in understanding the distribution and abundance of different species or types in a spatial region. One recent study has suggested that ecologic and evolutionary principles might provide a theoretical framework for linking diversity analysis from clinical imaging with regional variations in blood flow, cell density, and necrosis. 21 Drawing upon these studies, we investigated the spatial heterogeneity characteristics of the tumor by using habitat diversity analysis, drawing from methodology in ecological statistics literature. The tumor region is treated as an ecological community, and the spatial diversity of multiple tumor habitats [defined radiologically based on T1 postcontrast and T2-fluid attenuated inversion recovery (FLAIR) 22 intensity] is assessed. T1 postcontrast images and T2 FLAIR MR images represent different tissue characteristics within the tumor. For example, characteristics such as perfusion and extravasation of the contrast agent could be determined by T1-weighted MRI sequences, and interstitial edema and cell density could be determined by T2 FLAIR MRI sequences.
In this study, we obtained various ecological diversity indices such as Shannon index, Simpson index, and Fisher's alpha to quantify the habitat diversity of the tumor. These measurements (features) were then used to investigate the association with 12-month overall survival (OS) status as well as driver status of the epidermal growth factor receptor (EGFR) gene (i.e., identifying those tumors driven by EGFR alteration), using a classification framework. Our goal was to determine if such radiographic features could be used as reliable surrogates for OS and tumor molecular (specifically, EGFR driven) status. Driver genes pertain to tumor initiating or maintaining molecular alterations and have been defined based on the combination of mutation events as well as DNA copy number changes (like amplifications or deletions). Several driver genes for GBM have been defined and include genes like phosphatase and tensin homolog (PTEN), EGFR, DNA-damage-inducible transcript, platelet-derived growth factor receptor (PDGFRA), and neurofibromin 1. 23 EGFR is the main regulator of cell function and tumorigenesis in GBM and is one of the most widely recognized driver alterations in this disease. EGFR signaling has been shown to modulate gliomagenesis and constitutes one of the key molecular events underlying the classical subtype. 24 EGFR alterations also provide the basis for therapeutic intervention based on receptor tyrosine kinase (RTK) inhibitor therapies. 25 To the best of our knowledge, spatial diversity analysis of tumor habitats for quantitative imaging data is a novel investigation in neuroradiology as well as in radiomics. The goal of this study was to examine the feasibility of using spatial diversity features obtained from tumor habitats within MR images as reliable surrogates of 12-month OS status as well as tumor driver gene status in patients with GBM. This study was formulated based on reported observations about phenotypic consequences of molecular aberrations in GBM, specifically, changes in proliferation, invasion characteristics of the tumor, as well as associated patient survival. Apart from examining such feasibility, this work attempts to provide a characterization of the spatial variation in radiological habitat abundance across the tumor region, complementing previous studies of habitat abundance. 21, 22 In addition, aside from providing a new set of features for radiomic characterization of GBMs, our study of associations with both survival and EGFR status pertains to various ongoing investigations in imaging-genomics analysis as well. 26, 27 2 Materials and Methods
Data
A dataset of 65 patients (21 females and 44 males) with primary, untreated GBM were studied based on the availability of postcontrast T1-weighted and T2-weighted FLAIR image from The Cancer Imaging Archive (TCIA). 28 These patients were selected such that their genomic (specifically EGFR mutation and copy number status), clinical, and companion imaging data were available from either The Cancer Genome Atlas (TCGA) portal or TCIA portal. Clinical data regarding tumor driver gene status and OS were obtained from the cBioPortal. 29 Patient demographics are summarized in Table 1 .
Genomic and Survival Data Processing
The first classification task pertains to the assessment of EGFR driver status in the tumor based on image-derived spatial diversity features from radiologically defined tumor habitats. Specifically, we aim to identify EGFR-driven GBMs from non-EGFR driven GBMs based on image-derived spatial diversity characteristics of tumor habitats. Tumor driver gene status was assessed using the combination of gene mutation and copy number change. Specifically, a gene is designated a "driver" if it has both a mutation as well as an amplification or deletion event in a tumor sample. Using prior studies of driver alterations in GBM, 23, 30 we assessed the frequency of driver status for each of the 32 genes studied for GBM. We only focused on drivers with a frequency larger than 20% in the dataset to avoid minority-sampling biases during classifier training. Table 2 shows the top five frequencies of each driver gene in the dataset. Only one of the 32 genes met this threshold-EGFR. We designated each of the 65 tumor cases to be EGFR driven or not, based on whether or not EGFR was both mutated and altered (by copy number) in that patient's tumor. This binary designation is subsequently used as the class label in the classification task.
In this study, we also investigated if the image-derived spatial diversity features (specifically, diversity characteristics of radiologically defined tumor habitats) are associated with OS status at the 12-month time point. This choice of cutoff is based on the median survival times of GBM (12 to 15 months) and has been The values in age and overall survival are mean AE standard deviation. used in other studies as well. 31 For this analysis, the patients were assigned to one of two groups according to their OS at 12 months. 31 One group had 26 patients with OS of 12 months or less, and the other group had 39 patients with OS greater than 12 months.
Image Preprocessing
Image registration, nonuniformity correction, reslicing, and intensity normalization were performed as preprocessing procedures before analyzing the data for spatial diversity features. The registration of the T1 postcontrast images and T2 FLAIR images as well as nonuniformity correction for the artifacts in MRI were performed using medical image processing, analysis, and visualization software. 32 Images were subsequently resliced for isotropic pixel resolution using the NIFTI toolbox in MATLAB. Example T1 postcontrast and T2 FLAIR images are shown in Fig. 1 .
Delineation of Tumor Habitats and Their Spatial Point Patterns in the Tumor Region of Interest
The segmentation of the tumor region was performed by experts (J.M. and G.R.) semiautomatically using the Medical Image Interaction Toolkit. 33 The slice with the largest tumor area in T1 postcontrast image and the corresponding slice in the T2 FLAIR image was selected for analysis. Each pixel in the tumor region from the T1 postcontrast and T2 FLAIR images was assigned to one of two groups according to its intensity, respectively. The threshold between the two intensity groups was determined based on a Gaussian mixture model 34 to assign each tumor pixel to a low-intensity or high-intensity group. These two (T1 postcontrast and T2 FLAIR) regions are combined into a region of interest (ROI) for habitat analysis, as the union of T1 postcontrast and T2 FLAIR tumor regions. The tumor ROI is treated as an ecological community. 20, 21 For spatial diversity analysis, the tumor ROI is divided into 8 × 8 pixel square regions, called "quadrats." Each pixel in each quadrat is designated a "type" (or species) based on the intensity group it belongs to (T1-low, T1-high, FLAIR-low, and FLAIR-high). This creates a spatial point pattern across all the quadrats in the tumor region. Figure 2 illustrates this paradigm.
Spatial Diversity Features
Using the spatial point pattern obtained above, we obtained a range of diversity features over the tumor habitats, 22 based on their relative abundance in the tumor region. 35 First, the number of pixels in each quadrat was counted for each "type" (low or high intensity in T1 and FLAIR images), which gave us the abundance of each point type (or species) within the given quadrat. Subsequently, a species-abundance matrix was obtained. Each row represents a quadrat, and each column represents the abundance of each of the four species (T1-low, T1-high, . Two-dimensional grid lines were overlaid on each binary mask and were equally spaced at with the distance of 8 pixels. Each square site in the partitioned tumor region is called a "quadrat." The different gray level intensity areas represent radiologically defined combinations of different types. Top-left of the figure shows an example quadrat (32nd site) of this ROI and the species abundance matrix can be constructed from these quadrats by enumerating the pixels belonging to each of the four intensity groups (bottom-left of the figure).
FLAIR-low, FLAIR-high intensity groups) in that quadrat. Next, the various diversity features were calculated from this species-abundance matrix. In this study, 36 diversity features were calculated (across all the quadrats in the tumor ROI) using the R package (vegan), 36 all of which are listed in Table 3 . Shannon, Simpson, inverse Simpson, Fisher indices, and Pielou's evenness are popular diversity indices representing quantitative measures that reflect the abundance of different point types in a spatial region. The definitions of these indices are explained in the Appendix. In addition to the aforementioned indices, we used functions from the "vegan" R-package for nestedness indices, Kendall indices (Kendall coefficient of concordance), and alpha, beta, as well as gamma diversity. 36 Nestedness indices find multiarea dissimilarities and decomposes these into components of turnover and nestedness, 37 and the Kendall index performs a posteriori tests of the contributions of individual types to the concordance of their group. 36 Alpha, beta, and gamma diversity were introduced by Whittaker 38, 39 to represent the species richness of an area or the number of species in a habitat, differentiation among sites, and the richness of species present within a large area, respectively.
Statistical Analysis
A total of 36 diversity features that consist of the mean, standard deviation, skewness, and kurtosis (computed across all the quadrats in the tumor region) of the diversity indices such as the Shannon index, Simpson diversity index, inverse Simpson index, Fisher's alpha, Pielou's evenness index, nestedness and Kendall indices, and spatial measure of richness (alpha, beta, and gamma diversity) were computed from the measurement of abundance from the quadrats of ROIs. For examining association with 12-month survival, we used five diversity features: Kendall index (T1-high), Kendall index (T1-low), mean Fisher's alpha, skewness of the inverse Simpson, and standard deviation of Fisher's alpha. These five features were selected based on the overall coefficient of variation (CoV) across the dataset. These features were used to discriminate OS at the 12-month time point (>12 months or ≤12 months). For classifier modeling, we used a symbolic regression method, 40 with threefold cross validation for assessment of classifier performance. Difference of the classifier's performance [using area under the receiver operating characteristic (ROC) curve, AUC] 41 relative to random classification (AUC ¼ 0.5) is assessed via p-value from a Mann-Whitney hypothesis test (using R-package, "verification"). 42 We used the Brier score to measure the accuracy of prediction using Eq. (1). The Brier score is a commonly used performance measure for assessing the accuracy of probability predictions, defined as E Q -T A R G E T ; t e m p : i n t r a l i n k -; e 0 0 1 ; 3 2 6 ; 3 1 5
where N is the sample size, f i is the probability that was forecast, and o i is the actual outcome of the event at instant i. This score ranges from 0 (for a perfect prediction) to 1 (for a prediction that is incorrect on every case). The predictive accuracy of the diversity features, true positive rate (TPR), and true negative rate (TNR) for the survival groups were assessed based on an operating point selected along the ROC to maximize the sum of sensitivity and specificity. The accuracy was calculated using Eq. (2) for the optimal model:
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where TP, FP, TN, and FN represent true positive, false positive, true negative, and false negative rates, respectively. The same procedure was followed to obtain a classifier to discriminate EGFR-driven tumors from tumors that were not EGFR driven using the top five features based on CoV: Kendall index of the T1-high species, Kendall index of the T1-low species, mean Fisher's alpha, skewness of the inverse Simpson, and standard deviation of Fisher's alpha, across all quadrats within the tumor.
Results
We dichotomized the OS at 12 months, 1,2 yielding a binary label on the cases. This was used to build the classifier using symbolic regression. We computed the p-value and Brier score to assess the classifier's prediction of 12-month survival. The AUC was 0.74 and the corresponding p-value is 0.00021 indicating that the AUC for association with survival status at the 12-month point (>12 months or ≤12 months) is significantly different from random classification (AUC ¼ 0.5). The Brier score (measures the accuracy of probabilistic predictions) was 0.197 for the survival prediction task. Figure 3 shows the ROC curve with AUC and confidence intervals to illustrate the performance of this binary classifier. At the chosen operating point along the ROC (chosen to maximize the sum of sensitivity and specificity), the sensitivity ¼ 0.75 and specificity ¼ 0.59. The results of the ROC analysis with confidence intervals are shown in Fig. 3 and Table 4 .
In the ROC analysis for EGFR-driven tumor identification, the AUC is 0.845 and the corresponding p-value is 1.56 × 10 −7 indicating that this AUC is also significantly different from random classification (AUC ¼ 0.5). At an operating point (sensitivity ¼ 0.83, 1 − specificity ¼ 0.24) determined by maximizing the sum of sensitivity and specificity, the TPR and TNR are thus 0.77 and 0.83, respectively. The corresponding accuracy is 0.79. The Brier score, for the task of predicting driver gene status of EGFR, was 0.147, again suggesting good classifier performance. Figure 4 shows the ROC curve with confidence intervals for identification of EGFR-driven tumors, and the results are summarized in Table 5 .
Discussion
In this work, we present a methodology to determine the ability of spatial habitat diversity features from radiologically defined tumor habitats to investigate the association with the 12-month survival of patients with GBM as well as the driver status of the EGFR gene. The case IDs for the 65 glioblastoma patients are listed in Table 6 . In this study, we defined four distinct groups based on tumor intensity obtained from different MR sequences. These groups are considered as different species within an ROI; subsequently, we performed spatial diversity analysis using various measures of species distribution within the tumor. Our findings show that diversity features obtained from MR images are associated with 12-month OS and EGFR driver status in GBM patients. In this study, we used the top five features based on CoV, which are Kendall index (from the T1-high group), Kendall index (T1-low group), mean Fisher's alpha, standard deviation of Fisher's alpha, and skewness of the inverse Simpson, across the tumor's quadrats. These spatial diversity features are based on the following diversity indices: the Kendall coefficient of concordance is a nonparametric statistic and is a measure of agreement or association among species. Fisher's alpha is a parametric diversity index and assumes that species abundance follows logarithmic distribution, which can predict the number of types at different levels of individual points. Inverse Simpson diversity index is a reciprocal Simpson's index and Simpson's index measures the probability that two individuals (points) randomly selected from a sample will belong to the same type. In our case, the Kendall index evaluates the degree of similarity of individual species to the overall concordance of their groups. The mean and standard deviation of Fisher's alpha indices indicate that the average and the In the ROC analysis, we determined an operating point based on maximizing the sum of sensitivity and specificity. For association with 12-month survival, the TPR (0.59), TNR (0.75), accuracy (0.67) at this optimal point, and AUC of 0.74 were relatively high, indicating that species diversity features can discriminate the survival classes of GBM. In addition to assessing the predictive ability for discriminating survival status of patients with GBM, we also assessed performance in predicting the driver status of the EGFR gene in these tumors. Mutation in the EGFR gene has been associated with a number of cancers including GBM. Our findings indicate that EGFR-driven GBMs can be classified with high AUC of 0.85, as well as high TPR (0.76), high TNR (0.83), and high accuracy of 0.79 (at the chosen operating point along the ROC) based on the tumorderived spatial diversity features. This suggests a potential relationship between habitat diversity and driver gene status of the EGFR gene, with potential value for the prioritization of appropriate candidate therapies (e.g., RTK inhibitors targeted to EGFR alteration). 25 In this study, EGFR was picked only because in the dataset of the 65 patients, this was the only gene with more than 20% frequency of driver-event occurrence within the dataset. There are multiple known drivers for GBM (e.g., PTEN, PDGFRA, etc.), and indeed, it would be very interesting to study their status as a function of spatial diversity. However, their occurrence in the dataset was low and thus, it was infeasible to build a classifier to predict driver status reliably. For future work, other investigations could include noninvasive assessment of pathway activity (rather than single gene entities). This would permit the assessment of groups of genes participating in tumorogenesis, rather than individual pathway components, perhaps being more relevant to the systems biology of the disease.
In this study, we have shown that radiologically defined habitat features are potential surrogates of both OS and EGFR status and can be used as prognostic tools as well as for noninvasive assessment of EGFR-driven tumors (this could have value for determining eligibility for EGFR-targeted therapies). However, there are some limitations. As with almost any retrospective analysis of multisite radiology data, one potential limitation in our study was the variation in scanning and acquisition protocols across MRI systems within the publicly available TCIA database. Although we performed intensity normalization to account for some of this variation, the impact of such variation in image resolution on spatial diversity features needs to be examined more systematically. Further, variation across cancer treatment regimens, such as surgery, radiation, and chemotherapy, may have an effect on the survival rates of the patients as well. Also, the assessment of the predictive utility of these spatial diversity features in an independent validation cohort with matched clinical characteristics is essential to assess their prognostic reliability and robustness. Finally, since habitat abundances have been shown to be associated with survival, 22 the role of these diversity features in the context of clinical variables like age, Karnofsky score, and habitat abundance will be useful to understand the added predictive value of these spatial diversity features. In this study, we used spatial diversity analysis of radiological habitats to investigate spatial heterogeneity characteristics of the tumor for their association with 12-month survival and EGFR driver gene status of patients with GBM. This type of diversity analysis is, to the best of our knowledge, a novel way to analyze multiparametric MRI data. As alluded to earlier, such an investigation is pertinent to both radiomics and radiogenomic analysis paradigms. Specifically, we have focused on a new radiomic characterization of tumor diversity, based on radiologically defined habitats. Further, these features have been used to assess relationships with genomic events in the tumor, namely, driver status of EGFR. This radiogenomics or imaging-genomic analysis reveals that image-derived features could serve as potential noninvasive surrogates of tumor biology. Thus, the spatial diversity of the habitats within the tumor might have information associated with the biology of the tumor. Figure 5 shows examples of ROI spatial habitat maps in a low survival patient (4.8 months) and a high survival patient (57.8 months). Also, Fig. 6 shows examples of different spatial habitat maps for three different diversity indices between low survival patients with EGFR-driven and high survival patients with non-EGFR driven tumors. The EGFR driver event, though an early event, could potentially initiate a phenotypic evolution of the tumor (that manifests itself as distinct spatial distributions of tumor habitats when assessed by MRI). It has been reported 43, 44 that the EGFR pathway regulates multiple key phenotypes such as cell proliferation, angiogenesis, invasion, and metastasis. These phenotypes have distinctly different characteristics in MRI. Our results suggest that the spatial diversity of radiologically observed habitats within the tumor region could act as a surrogate for the altered EGFR status. A mechanistic relationship can only be reliably inferred via in-vivo experiments and could be an interesting avenue for follow-up investigation. Such spatial diversity analysis of the tumor habitats 21 might provide an additional characterization of the tumor ecological landscape, complementing previous work on habitat abundance within tumors. 21, 22 Our studies in this cohort have shown that several habitat diversity features are associated with survival and EGFR driver gene status with ROC prediction accuracies of 0.67 for 12-month survival and 0.79 for EGFR driver gene status. However, we note that these results remain to be confirmed in an independent cohort of patients with GBM. Nonetheless, these results indicate that such tumor habitat features could potentially be a useful clinical prognostic tool in radiology studies, in addition to providing a noninvasive surrogate of tumor biology (via inference of underlying gene driver status). Further, though this study has been done using only two sequences, T1 postcontrast and T2 FLAIR, there is no conceptual barrier to doing this kind of analysis with more sequences in the multiparametric MRI context. Also, a principled study of driver status inference using radiology habitat features for all other GBM drivers 23 is a topic of future study, subject to the identification of a suitable clinical cohort with sufficient samples in both the driver and nondriver groups.
